Pharmaceutical

AdAlta and SYNthesis to form AdCella for advanced cancer treatments

AdAlta has signed an MOU with SYNthesis to explore the creation of a jointly owned special purpose entity, AdCella.

Apr 9, 2024 - 00:00
AdAlta and SYNthesis to form AdCella for advanced cancer treatments
AdAlta has signed an MOU with SYNthesis to explore the creation of a jointly owned special purpose entity, AdCella.
Read the original article

Tags:

Previous Article

Sensorion raises $16m for gene therapies to treat deafness

Next Article

Medicxi and Starpharma to develop dendrimer-based cancer treatments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pyxis cuts staff by 40% and pours resources into two cancer therapies

Pyxis cuts staff by 40% and pours resources into two ca...

Nov 8, 2023

STAT+: FDA gives a mixed response to a petition seeking greater clinical trial transparency

STAT+: FDA gives a mixed response to a petition seeking...

Feb 23, 2024

Mirum applies for extended use of PFIC therapy in Europe

Mirum applies for extended use of PFIC therapy in Europe

Apr 6, 2023